BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 37234004)

  • 1. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
    Ascef BO; Almeida MO; Medeiros-Ribeiro AC; Oliveira de Andrade DC; Oliveira Junior HA; de Soárez PC
    JAMA Netw Open; 2023 May; 6(5):e2315872. PubMed ID: 37234004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis.
    Ascef BO; Almeida MO; de Medeiros Ribeiro AC; Andrade DCO; de Oliveira Júnior HA; Pereira TV; de Soárez PC
    Syst Rev; 2021 Jul; 10(1):205. PubMed ID: 34274019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis.
    de Oliveira Ascef B; Almeida MO; de Medeiros-Ribeiro AC; de Oliveira Andrade DC; de Oliveira Junior HA; de Soárez PC
    Sci Rep; 2023 Aug; 13(1):13699. PubMed ID: 37607959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic interventions for fatigue in rheumatoid arthritis.
    Almeida C; Choy EH; Hewlett S; Kirwan JR; Cramp F; Chalder T; Pollock J; Christensen R
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD008334. PubMed ID: 27271314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
    Ho Lee Y; Gyu Song G
    Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
    Caporali R; Allanore Y; Alten R; Combe B; Durez P; Iannone F; Nurmohamed MT; Lee SJ; Kwon TS; Choi JS; Park G; Yoo DH
    Expert Rev Clin Immunol; 2021 Jan; 17(1):85-99. PubMed ID: 33305638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
    Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
    Cohen SB; Alten R; Kameda H; Hala T; Radominski SC; Rehman MI; Palaparthy R; Schumacher K; Schmitt S; Hua SY; Ianos C; Sewell KL
    Arthritis Res Ther; 2018 Jul; 20(1):155. PubMed ID: 30053896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
    Strand V; Balsa A; Al-Saleh J; Barile-Fabris L; Horiuchi T; Takeuchi T; Lula S; Hawes C; Kola B; Marshall L
    BioDrugs; 2017 Aug; 31(4):299-316. PubMed ID: 28612180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis.
    Tanaka E; Kawahito Y; Kohno M; Hirata S; Kishimoto M; Kaneko Y; Tamai H; Seto Y; Morinobu A; Sugihara T; Murashima A; Kojima M; Mori M; Ito H; Kojima T; Sobue Y; Nishida K; Matsushita I; Nakayama T; Yamanaka H; Harigai M
    Mod Rheumatol; 2022 Jan; 32(1):74-86. PubMed ID: 33706664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.